Global Janus Kinases (JAKs) Inhibitor Drugs Market – Industry Trends and Forecast to 2030

Janus Kinases (JAKs) Inhibitor Drugs Market Analysis and Size

Many Janus kinase (JAK) inhibitors have been approved to treat inflammatory and autoimmune illnesses and chronic hemopoietic neoplasms. The World Health Organization database was used to collect pharmacovigilance data for this retrospective observational investigation. Adverse events are grouped according to the Medical Dictionary for Regulatory Activities hierarchy. Including ruxolitinib, tofacitinib, or baricitinib as a suspected medicine was extended until February 28, 2021, in all Individual Case Safety Reports (ICSRs). Through disproportionality research, the information component (IC) was identified. A negative occurrence was considered a significant signal if the lower end of the IC's 95% believability interval (IC025) was positive. As a result, these factors will accelerate market growth.

Data Bridge Market Research analyses that the Janus kinases (JAKs) inhibitor drugs market, which is USD 2.45 billion in 2022, is expected to reach USD 5.11 billion by 2030, at a CAGR of 9.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Janus Kinases (JAKs) Inhibitor Drugs Market Scope and Segmentation  

Market Definition

Janus kinase (JAKs) inhibitors prevent the aberrant action of JAK family enzymes, including JAK1, JAK2, JAK3, and TYK2. These enzymes' suppression contributes to the JAK-STAT signaling pathway, which is essential for the emergence of several autoimmune diseases and cancer indicators. JAK inhibitors are part of the medications known as DMARDs (disease-modifying antirheumatic drugs). The FDA has approved the use of three JAK inhibitors, baricitinib (Olumiant), tofacitinib (Xeljanz), and upadacitinib (Rinvoq), to treat rheumatoid arthritis.

Janus Kinases (JAKs) Inhibitor Drugs Market Dynamics

Drivers

• The rising introduction of novel drugs will propel the market growth

Psoriatic arthritis is a type of arthritis characterized by red skin patches that are covered with silvery scales. Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for treating rheumatoid arthritis (RA). Tofacitinib is a Janus kinase inhibitor that controls cytokine signaling in inflammation and the immune system. The introduction of novel drugs and alternatives will probably cause the global Janus kinase (JAKs) inhibitor drugs market to grow throughout the forecast period. For treating adult patients with psoriatic arthritis, Pfizer Inc. received FDA approval for XELJANZ (TOFACITINIB) in December 2017.

• Rising R&D activities will propel the market growth

The manufacturing of new Janus kinase inhibitors is the focus of major pharmaceutical corporations and academic organizations—for instance, the M.D. Anderson Cancer Center and Incyte Corporation collaborated to perform phase -2 clinical studies (research was completed in March 2017) to evaluate ruxolitinib's effectiveness in managing advanced hematological malignancies. Jak1 and Jak2, kinase inhibitor ruxolitinib, prevent abnormal cells from proliferating. Therefore, the global market for these inhibitors is predicted to grow during the forecast period due to ongoing research and development of new Janus kinase inhibitor drugs.

Opportunities

• JAK inhibition in spondyloarthritis will act as an opportunity

Genetic, cellular, and molecular factors influence spondyloarthritis pathogenesis. Skin and gut barrier dysregulation, brought on by changes in bacterial exposure and/or inherited factors, causes inflammation of the skin, stomach, and joints. Immune cells travel to painful joints from the peripheral circulation. When immune cells such as mast cells, dendritic cells, macrophages, innate lymphoid cells, mucosal-associated invariant T lymphocytes, and other inflammatory mediators invade the tissue, they release many additional mediators. IFN, IL-6, IL-12, IL-17, IL-23, and TNF are examples of cytokines that play important roles in pathogenesis.

Restraints/Challenges

• Risks associated with Janus kinases (JAKs) inhibitors

The USFDA issued its most severe safety warning—black box labeling—in response to severe side effects, including thrombosis, infections, malignancies, and embolisms. Compared to TNF alpha inhibitors, Janus kinase (JAK) inhibitors used to treat chronic inflammatory illnesses have raised the risk of serious cardiovascular issues (such as heart attack or stroke), cancer, blood clots in the lungs, deep veins, serious infections, and death.

For instance, Pfizer has recently struggled to promote its RA medication Xeljanz due to regulatory agencies' worries over significant cardiovascular adverse effects and cancer risk. According to recent studies, the marketing problem will only become worse. More than 4,300 patients over 50 with RA and at least one cardiovascular risk factor participated in a study comparing Xeljanz to a TNF inhibitor. The USFDA required these patient characteristics for the study to be conducted and to clarify the decision regarding using a higher dose of Xeljanz.

This Janus kinases (JAKs) inhibitor drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Janus kinases (JAKs) inhibitor drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Janus Kinases (JAKs) Inhibitor Drugs Market Scope

The Janus kinases (JAKs) inhibitor drugs market is segmented on the basis of type, therapeutic area, indication, drugs, mode of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• JAK1 Inhibitor
• JAK2 Inhibitor
• JAK3 Inhibitor
• Others

 Therapeutic Area

• Oncology
• Musculoskeletal
• Gastroenterology
• Others

 Indication

• Autoimmune disorders
• Rheumatoid arthritis
• Ulcerative Colitis
• Solid Tumors
• Hematological Malignancies
• Others

Drugs

• Baricitinib
• Tofacitinib Citrate
• Upadacitinib
• Others

Mode of Administration

• Injectable
• Oral
• Others

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Janus Kinases (JAKs) Inhibitor Drugs Market Regional Analysis/Insights

The Janus kinases (JAKs) inhibitor drugs market is analysed and market size insights and trends are provided by country, type, therapeutic area, indication, drugs, mode of administration, distribution channel and end user as referenced above.

The countries covered in the Janus kinases (JAKs) inhibitor drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the Janus kinases (JAKs) inhibitor drugs market because of the region's well-developed healthcare infrastructure, favorable reimbursement policies, and high prevalence of different autoimmune diseases.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030, owing to the high presence of major manufacturers across the areas and growing JAKAFI adoption.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Janus Kinases (JAKs) Inhibitor Drugs Market Share Analysis

The Janus kinases (JAKs) inhibitor drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Janus kinases (JAKs) inhibitor drugs market.

Some of the major players operating in the Janus kinases (JAKs) inhibitor drugs market are:

• AbbVie Inc (U.S.)
• Pfizer Inc (U.S.)
• Galapagos NV (Belgium)
• Gilead Sciences, Inc (U.S.)
• Theravance Biopharma (U.S.)
• Incyte (U.S.)
• Eli Lilly and Company (U.S.)
• CTI BioPharma Corp (U.S.)
• Sierra Oncology, Inc (U.S.)
• Novartis AG (Switzerland)
• Sanofi (France)
• CELGENE CORPORATION (U.S.)
• Vertex Pharmaceuticals Incorporated (U.S.)
• Astellas Pharma Inc (Japan)
• Amneal Pharmaceuticals LLC (U.S.)
• AstraZeneca (U.K.)
• Aclaris Therapeutics, Inc (U.S.)
• BIOCRYST PHARMACEUTICALS, INC (U.S.)
• Biogen (U.S.)
• Reistone Biopharma (China)

SKU-50132